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Government and societal efforts to combat obesity are aimed at prevention, although there is a generation for
whom excess weight is the rule rather than the exception. Although measures to prevent a worsening of the
current epidemic are important, management of obesity must also be prioritised. Obesity management is beset
with problems ranging from attitudinal to clinical and pharmacological, and the individualisation of therapy.
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Obesity prevention has failed. If nobody in the UK gains
another single ounce, there are enough already obese
people to make epidemics of diabetes, then heart disease,
then premature death inevitable. The job of Primary Care
is to manage obesity, although this may not involve the
loss of a single ounce: their role is often misunderstood,
especially by departmental and Government bodies, and
especially by the Quality and Outcomes Framework
(QOF) which perversely incentivises maintaining excess
weight in order to bulk up the obesity register without a
finger being lifted to introduce screening or management
of the condition.Prevention
However, three-quarters of the population have avoided
obesity – although more than half of those are over-
weight - so measures must be taken to prevent weight
gain in the public health environment. The National
Obesity Forum behavioural expert Damian Edwards
undertook a social experiment in a Salford supermarket,
involving measures such as rearranging shelves to make
healthy food more accessible and placing life-size cut
outs of smiling local general practitioners (GPs) and
nurses indicating the fruit and vegetables. These simple
changes carried out overnight, increased fruit consump-
tion by almost 30% compared to control [1]. This, and
other simple changes, such as removing sweets from theCorrespondence: dwhaslam@aol.com
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2014checkout, and changing the GP incentive QOF to reward
obesity management, would have an instant beneficial
effect on the health of the Nation. Other measures will
take longer – the Action on Sugar campaign will spe-
cify targets for food reformulation, but will take several
years to make a big difference; changes to the built en-
vironment to promote activity might take a generation
to have an effect. Industry, public health and Government
have a major role to play, and the political power
wielded by the food and retail industries may thwart
change. Other proven determinants of obesity, such as
genetic and epigenetic influences, gut microbiota and
adenovirus infections, may never alter.Management
Primary care bears the brunt of obesity management;
obese patients may present for weight loss advice, may
attend clinics such as diabetes or cardiovascular disease
(CVD) clinics as a secondary problem to their weight,
or, more likely, will attend with something entirely unre-
lated to their weight, which could be as diverse as holi-
day jabs to a black eye. The unique challenge for the GP
or nurse is to engage the latter group effectively and
inoffensively, a conversation which represents the start
of the obesity management programme. This process
may only take the last two minutes of an unrelated
consultation – engagement occurs, weight and blood
pressure are measured, blood tests organised and more
comprehensive follow-up assured. Thus, the initial phase
of weight management is the assessment of baseline char-
acteristics and the rapid correction of possible features,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Other common co-existing conditions which may not
have presented as symptoms in their own right and can
easily be screened for, include sleep apnoea, nonalcoholic
steatohepatitis (NASH) and polycystic ovarian syndrome.
The remaining aspect of obesity management is
attempting to induce weight loss and maintenance.
Major weight loss is difficult to induce in primary care
as demonstrated by studies such as Counterweight [2]
and Camwel [3] which struggled to induce and main-
tain meaningful weight loss. On the other hand, the
Look Ahead study [4] showed that long term weight
loss is sustainable, linked with improvements in lipids
and blood pressure, but in an intervention too inten-
sive to be transferable to primary care. Similarly, the
Diabetes Prevention Programme [5] and the Diabetes
Prevention Study [6], although similarly untransferable
to routine community interventions, show that remarkably
small degrees of weight loss – less than a kilogramme
per year – confer 58% reduction (in both studies) in
the cumulative incidence of diabetes.
Cornerstones of obesity management in primary care
are diet, physical activity and behavioural therapy.
Low-carbohydrate diets are increasing in popularity
following studies, such as A-to-Z [7], which demon-
strate their effectiveness. Exercise on prescription has
limited evidence for benefit, and building activity into
routine daily life is important [8] although scheduled
exercise does have cardiometabolic benefit. Behavioural
therapy involves elements such as goal setting, stimulus
control, cognitive restructuring and relapse prevention,
which tend naturally to be done as part of the conversa-
tion on diet and physical activity.
Pharmacotherapy
Pharmacotherapy for obesity is restricted to orlistat,
which induces weight loss by blocking the action of
pancreatic and gastric lipase, reducing absorption of
fat by up to one-third. The unabsorbed dietary fat is
excreted through the intestine. More importantly, it
reduces the cumulative incidence of diabetes and has
been shown to reduce total and LDL cholesterol and
increase HDL:LDL ratio [9].
Sibutramine is a centrally acting satiety enhancer,
which was popular, effective and well-tolerated prior to
its withdrawal in 2010. The SCOUT study [10] showed
an increase in non-fatal CV events in patients with
already existing diabetes and CVD but had no stopping
criteria, so non-responders continued the drug for five
times longer than the clinical licence allowed. The
sibutramine was withdrawn on the grounds that any
obese person could have latent CVD; however, a subse-
quent sub analysis [11] proved that had the licence
been followed, even in these high risk patients, andnon-responders taken off the drug, then mortality was
reduced. Furthermore, two anti-obesity drugs authorised
in the US by the Food and Drug Administration (FDA) –
Qsymia and Belviq - were rejected in Europe on the
spurious grounds that they might be used for reasons
other than those for which they were intended. A third –
Contrave – was delayed by the FDA awaiting CV outcome
studies. In treating obesity in the context of serious
chronic disease, clinicians require licensing authorities
to look at the benefits of obesity reduction in treating
and preventing diabetes, CVD, NASH and so on. Taking
into account the controversial withdrawal of rimonabant
in 2008, there are five times as many drugs withdrawn
or remaining unlicensed, than there are drugs available
for prescription. Liraglutide, an injectable glucagon-like
peptide 1 (GLP-1) agonist already being used to treat
diabetes, has been filed at a higher dose for the manage-
ment of obesity [12].
Primary care is also where most of the bariatric surgery
programme takes place – everything from engagement
to death, apart from the brief technological interlude
of surgery and immediate follow-up.
In managing obesity and its associated risk factors and
co-morbidities, clinicians encounter problems, as man-
aging one individual element may exacerbate another.
In particular, glucose-lowering agents, specifically in-
sulin, sulphonylureas and thiazoledinediones have had
the demoralising and unhealthy side effect of weight
gain. Both β-blockers and thiazide diuretics increase
the risk of diabetes; sibutramine induced weight loss
but raised blood pressure; statins improve lipid profile but
increase the risk of diabetes; niacin increases HbA1c
whilst lowering cholesterol; torcetrapib was withdrawn
from phase 3 trials despite enormous improvements in
lipid profile because of an increase in blood pressure
and stroke risk; β-blockers reduce blood pressure but
increase the risk of obesity, partly by inducing more
sedentary behaviour. Progress has been made with the
advent of DPP-4 inhibitors, GLP-1 agonists and SGLT-
2 inhibitors: glucose lowering agents which are weight
neutral or induce weight loss and have various other
beneficial effects on cardiometabolic parameters.
The obesity paradox
Although a precursor of cardiometabolic diseases and
cancer [13], the presence of obesity may protect against
mortality once these conditions have occurred. It has
been commented that ‘the idea that a known risk factor
somehow transforms into a ‘protective’ agent after an
occurrence of a vascular clinical event is both surreal
and troubling’ [14]. This effect is termed the ‘Obesity
Paradox’. Increased body mass index (BMI) is a determin-
ant for heart failure (HF): for every 1 unit increase in BMI,
risk of HF increases by 5% in men and 7% in women.
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meta-analysis of 28,209 recruits [15] showed a reduc-
tion in CV mortality of 40% and all-cause mortality of
33%. In a review of trials including 250,000 individuals
with coronary artery disease, cardiovascular and mor-
tality outcomes were better in overweight and ‘mildly’
obese patients compared with ‘normal’ weight [16]. The
INVEST [17] study included 22,500 individuals with
hypertension and coronary artery disease, and demon-
strated a lower mortality and major CV events in the
overweight and obese compared to those of normal
weight. Various reasons have been postulated for the
paradox: fat may genuinely exert a protective influence
through unknown mechanisms, possibly through improved
metabolic reserve, or obesity may lead to individuals
becoming identified earlier as high risk, and treated
earlier and more vigorously with antihypertensive agents
and statins. An interesting thesis suggests that individuals
who only had HF because of weight gain, are naturally
less susceptible to the disease and, therefore, have a
more favourable prognosis [18]. Others suggest that
lower weight might be due to intercurrent illness or be
smoking-related, or that BMI is used inappropriately
as a measure of adiposity, although recent studies ad-
justed for these factors [13]. A post-hoc analysis of the
PROactive study of pioglitazone assessed the obesity
paradox, with interesting results [19]. In patients with
type 2 diabetes mellitus (T2DM) and CVD, the lowest
mortality was with BMI 30 to 35, whereas those with
BMI <22 had higher all-cause mortality. Active weight loss
was associated with increased mortality and hospitalisa-
tion: loss of ≥7.5% body weight (seen in 18.3% of patients)
was the strongest predictor of impaired survival whereas
weight gain was not associated with increased mortality.
The positive relationship between obesity and mortality is
attenuated with age, implying that excess weight may act
as a protective factor in established chronic disease [20].
Conclusions
Nobody attends their GP asking for their obesity to be
prevented; obesity has occurred by the time the health care
professional becomes involved. The most important point
in the obesity management programme is the initial engage-
ment of the patient followed by screening and risk manage-
ment. Weight loss is appropriate and should be encouraged
in many patients, but individualisation of care is important
so that the wrong patients do not have weight loss induced,
and those who would benefit from maintaining weight are
properly identified. Prevention of obesity and, therefore,
chronic disease is the domain of Government, public health
and industry and should be urgently prioritised.
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